News >

FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer

OncLive Staff
Published: Thursday, Oct 25, 2018

The FDA has granted a priority review to a supplemental new drug application (sNDA) for TAS-102 (trifluridine/tipiracil; Lonsurf) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction (GEJ).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication